Acute clinical benefits of a new inotropic agent AR-L 115 BS after i.v. and oral administration.
AR-L 115 BS is a new active noncatecholamine, non glycoside phenyl-imidazo-pyridine derivative inotropic agent. It has a strong inotropic effect in experimental animals. Its effectiveness and associated adverse effects were tested in 23 patients with severe heart failure (NYHA class III to IV). Intravenous administration of AR-L 115 BS at 1.4 mg/min for 6 hours in 11 patients increased cardiac index from 2.07 +/- 0.13 to 2.99 +/- 0.203 l/min/m2 (p less than 0.005) while pulmonary wedge pressure decreased from 23 +/- 2 to 13 +/- 2 mm Hg (p less than 0.005). Systemic vascular resistance fell from 1759 +/- 137 to 1263 +/- 71 dynes.sec. cm-5 (p less than 0.005). Heart rate and blood pressure remained unchanged. Following oral administration (450 mg) in 12 other patients, cardiac performance was similarly improved. Hemodynamic changes were apparent as early as 60 min after administration, and the duration of action ranged from 5 to 7 hours. No serious arrhythmias or side effects occurred. It could therefore be useful in the management of congestive heart failure.
D000284:Administration, Oral; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D002316:Cardiotonic Agents; D007093:Imidazoles; C029758:sulmazole